Edition:
United Kingdom

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

9.84USD
6:50pm GMT
Change (% chg)

$-0.08 (-0.81%)
Prev Close
$9.92
Open
$10.01
Day's High
$10.28
Day's Low
$9.78
Volume
152,179
Avg. Vol
438,477
52-wk High
$19.80
52-wk Low
$7.85

Latest Key Developments (Source: Significant Developments)

Iovance Biotherapeutics Files For Mixed Shelf Offering Of Up To $250 Mln
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING.  Full Article

Iovance Biotherapeutics Q2 Loss Per Share $0.34
Monday, 6 Aug 2018 

Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.34.Q2 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.  Full Article

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Biolife Solutions Inc ::BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS.BIOLIFE SOLUTIONS - EXECUTED AGREEMENT TO SUPPLY CRYOSTOR CELL FREEZE MEDIA AND HYPOTHERMOSOL STORAGE AND SHIPPING MEDIA TO IOVANCE BIOTHERAPEUTICS.  Full Article

Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics Inc reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.31.Q3 GAAP loss per share $0.35.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Iovance Biotherapeutics Inc - ‍anticipates cash, cash equivalents and short-term investments as of December 31, 2017, to be in excess of $141.0 million​.  Full Article